SenzaGen H1’22: Sales beat our estimates - Redeye

Redeye provides its comments on SenzaGen’s 2022 half-year report. The sales came in at SEK 19.9m (SEK 5.0m), and better than we estimated (SEK 17m). In our view, the report is solid due to the sales increase, and we look forward to the second half of the year when we expect increased demand due to the OECD approval SenzaGen received during the summer. We adjust our estimates, resulting in a new Base Case of SEK 17 (16).

Länk till analysen i sin helhet: https://www.redeye.se/research/852285/senzagen-h122-sales-beat-our-estimates?utm_source=finwire&utm_medium=RSS